Latest & greatest articles for mammography

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on mammography or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on mammography and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for mammography

121. Screening mammography for women 40 to 49 years of age: a clinical practice guideline from the American College of Physicians. (PubMed)

Screening mammography for women 40 to 49 years of age: a clinical practice guideline from the American College of Physicians. Breast cancer is one of the most common causes of death for women in their 40s in the United States. Individualized risk assessment plays an important role when making decisions about screening mammography, especially for women 49 years of age or younger. The purpose of this guideline is to present the available evidence for screening mammography in women 40 to 49 years (...) of age and to increase clinicians' understanding of the benefits and risks of screening mammography.

2007 Annals of Internal Medicine

122. Screening mammography for women aged 40 to 49 years at average risk for breast cancer: an evidence-based analysis

Screening mammography for women aged 40 to 49 years at average risk for breast cancer: an evidence-based analysis Screening mammography for women aged 40 to 49 years at average risk for breast cancer: an evidence-based analysis Screening mammography for women aged 40 to 49 years at average risk for breast cancer: an evidence-based analysis Medical Advisory Secretariat Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation (...) of the quality of this assessment has been made for the HTA database. Citation Medical Advisory Secretariat. Screening mammography for women aged 40 to 49 years at average risk for breast cancer: an evidence-based analysis. Toronto: Medical Advisory Secretariat (MAS). Volume 7(1). 2007 Authors' objectives The aim of this review was to determine the effectiveness of screening mammography in women aged 40 to 49 years at average risk for breast cancer. The following questions were asked: Does screening

2007 Health Technology Assessment (HTA) Database.

123. Routine screening mammography in women older than 74 years: a review of the available data

Routine screening mammography in women older than 74 years: a review of the available data Routine screening mammography in women older than 74 years: a review of the available data Routine screening mammography in women older than 74 years: a review of the available data Galit W, Green M S, Lital K B CRD summary This review found that screening mammography in women aged over 75 years could reduce breast cancer mortality. These conclusions should be interpreted with extreme caution given (...) for additional relevant studies. Study selection Study designs of evaluations included in the review Initially it was intended to limit the review to randomised controlled trials, but as none were found the criteria were broadened to include observational studies. The included studies comprised retrospective cohort studies and one case-control study. Specific interventions included in the review Studies that assessed screening mammography were eligible for inclusion. In most, but not all of the included

2007 DARE.

124. Cost-effectiveness analysis of a quality-controlled mammography screening program from the Swiss statutory health-care perspective: quantitative assessment of the most influential factors

Cost-effectiveness analysis of a quality-controlled mammography screening program from the Swiss statutory health-care perspective: quantitative assessment of the most influential factors Cost-effectiveness analysis of a quality-controlled mammography screening program from the Swiss statutory health-care perspective: quantitative assessment of the most influential factors Cost-effectiveness analysis of a quality-controlled mammography screening program from the Swiss statutory health-care (...) -effectiveness of a mammography screening programme (MSP) aimed at reducing breast cancer, compared with an established opportunistic screening programme, in Switzerland. The authors concluded that the MSP was a cost-effective strategy, but it seems that there is high uncertainty around the findings. Overall, the study was carried out satisfactorily, with good reporting of the methods and results. Type of economic evaluation Cost-effectiveness analysis Study objective The primary objective of the study

2007 NHS Economic Evaluation Database.

125. Cost effectiveness of mammography screening for Chinese women

Cost effectiveness of mammography screening for Chinese women Cost effectiveness of mammography screening for Chinese women Cost effectiveness of mammography screening for Chinese women Wong I O, Kuntz K M, Cowling B J, Lam C L, Leung G M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment (...) on the reliability of the study and the conclusions drawn. CRD summary The study objective was to determine the cost-effectiveness of biennal screening with mammography, compared with no screening, for the detection of breast cancer in 40-year-old Chinese women. The authors concluded that when using epidemiological data for Chinese women, biennal screening was not a cost-effective alternative to no screening, given the low incidence of disease in this specific ethnic group. The study methodology appears

2007 NHS Economic Evaluation Database.

126. A systematic review of the effectiveness of magnetic resonance imaging (MRI) as an addition to mammography and ultrasound in screening young women at high risk of breast cancer

A systematic review of the effectiveness of magnetic resonance imaging (MRI) as an addition to mammography and ultrasound in screening young women at high risk of breast cancer Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2007 DARE.

127. Screening for breast cancer with mammography. (Full text)

Screening for breast cancer with mammography. A variety of estimates of the benefits and harms of mammographic screening for breast cancer have been published and national policies vary.To assess the effect of screening for breast cancer with mammography on mortality and morbidity.We searched PubMed (June 2005).Randomised trials comparing mammographic screening with no mammographic screening.Both authors independently extracted data. Study authors were contacted for additional information.Seven

2006 Cochrane PubMed

128. Does utilization of screening mammography explain racial and ethnic differences in breast cancer? (PubMed)

Does utilization of screening mammography explain racial and ethnic differences in breast cancer? Reasons for persistent differences in breast cancer mortality rates among various racial and ethnic groups have been difficult to ascertain.To determine reasons for disparities in breast cancer outcomes across racial and ethnic groups.Prospective cohort.The authors pooled data from 7 mammography registries that participate in the National Cancer Institute-funded Breast Cancer Surveillance (...) Consortium. Cancer diagnoses were ascertained through linkage with pathology databases; Surveillance, Epidemiology, and End Results programs; and state tumor registries.1,010,515 women 40 years of age and older who had at least 1 mammogram between 1996 and 2002; 17,558 of these women had diagnosed breast cancer.Patterns of mammography and the probability of inadequate mammography screening were examined. The authors evaluated whether overall and advanced cancer rates were similar across racial and ethnic

2006 Annals of Internal Medicine

129. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. (Full text)

Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. The Women's Health Initiative Estrogen-Aone trial comparing conjugated equine estrogens (CEE) with placebo was stopped early because of an increased stroke incidence and no reduction in risk of coronary heart disease. Preliminary results suggesting possible reduction in breast cancers warranted more detailed analysis.To determine the effects of CEE on breast cancers (...) and mammographic findings.Following breast cancer risk assessment, 10,739 postmenopausal women aged 50 to 79 years with prior hysterectomy were randomized to CEE or placebo at 40 US clinical centers from 1993 through 1998. Mammography screenings and clinical breast examinations were performed at baseline and annually. All breast cancers diagnosed through February 29, 2004, are included.A dose of 0.625 mg/d of CEE or an identical-appearing placebo.Breast cancer incidence, tumor characteristics, and mammogram

2006 JAMA PubMed

130. Computer-aided detection with full-field digital mammography

Computer-aided detection with full-field digital mammography Computer-aided detection with full-field digital mammography Computer-aided detection with full-field digital mammography BlueCross BlueShield Association Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. The BlueCross BlueShield Association Technology Evaluation Center website ( ) includes the most recent 3 (...) years of TEC Assessments. To request older reports, please use the “contact us” feature on the website. Citation BlueCross BlueShield Association. Computer-aided detection with full-field digital mammography. Chicago: BlueCross BlueShield Association (BCBS). TEC Assessment 21(3). 2006 Authors' objectives The objective of this assessment is to evaluate the impact of using computer-aided detection (CAD) vs. single reading on the sensitivity, specificity, and biopsy rates for full-field digital

2006 Health Technology Assessment (HTA) Database.

131. Full-field digital mammography

Full-field digital mammography Full-field digital mammography Full-field digital mammography BlueCross BlueShield Association Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. The BlueCross BlueShield Association Technology Evaluation Center website ( ) includes the most recent 3 years of TEC Assessments. To request older reports, please use the “contact us” feature (...) on the website. Citation BlueCross BlueShield Association. Full-field digital mammography. Chicago: BlueCross BlueShield Association (BCBS). TEC Assessment 20(16). 2006 Authors' objectives This assessment aims to update the July 2002 Assessment on full-field digital mammography and to compare cancer detection, recall, and biopsy rates for full-field digital mammography versus screen-film mammography. Authors' conclusions There is strong evidence showing that digital mammography is as accurate as film

2006 Health Technology Assessment (HTA) Database.

132. Should we recommend mammography screening for women between the ages of 40-50?

Should we recommend mammography screening for women between the ages of 40-50? Should we recommend mammography screening for women between the ages of 40-50? – Clinical Correlations Search Should we recommend mammography screening for women between the ages of 40-50? December 22, 2006 2 min read In a recent article in the Lancet, this question was addressed by a group of investigators led by Sue Moss, Ph.D. from the University of Leeds. Currently, the National Cancer Institute, U.S (...) . Preventative Health Services Task Force and the American Cancer Society all recommend screening at a younger age(those between 40-50). The task force, however, does recommend educating your patients about the potential risks/benefits regarding mammography at a younger age. Screening women older than 50 has been shown to reduce mortality from breast cancer by about 25%. Benefit in younger women has been previously suggested in multiple trials. In fact, a meta-analysis of the trials showed a 15% reduction

2006 Clinical Correlations

133. Cost-effectiveness of screening with contrast enhanced magnetic resonance imaging vs X-ray mammography of women at a high familial risk of breast cancer (Full text)

Cost-effectiveness of screening with contrast enhanced magnetic resonance imaging vs X-ray mammography of women at a high familial risk of breast cancer Cost-effectiveness of screening with contrast enhanced magnetic resonance imaging vs X-ray mammography of women at a high familial risk of breast cancer Cost-effectiveness of screening with contrast enhanced magnetic resonance imaging vs X-ray mammography of women at a high familial risk of breast cancer Griebsch I, Brown J, Boggis C, Dixon (...) drawn. Health technology The study compared three screening strategies aimed at women with a high risk of breast cancer. The strategies compared were mammography (XRM) alone, contrast-enhanced magnetic resonance imaging (CE MRI) alone, and a combination of XRM and CE MRI. CE MRI was conducted using a specific protocol with gadopentetate dimeglumine (Magnevists, Schering Healthcare) as the contrast medium (bolus intravenous injection of 0.2 mmol/kg body weight). Type of intervention Screening

2006 NHS Economic Evaluation Database. PubMed

134. Retrospective cost-effectiveness analysis of screening mammography (Full text)

Retrospective cost-effectiveness analysis of screening mammography Retrospective cost-effectiveness analysis of screening mammography Retrospective cost-effectiveness analysis of screening mammography Stout N K, Rosenberg M A, Trentham-Dietz A, Smith M A, Robinson S M, Fryback D G Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed (...) by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Several strategies for screening mammography and the subsequent treatment of breast cancer (BC) were examined. The primary strategy was screening mammography as implemented in the USA from 1990 to 2000. This consisted of screening all women aged 40 years or older annually or biennially. Sixty-four alternative mammography screening scenarios were considered, each with a particular fixed screening

2006 NHS Economic Evaluation Database. PubMed

135. Digital mammography: an update

Digital mammography: an update Digital mammography: an update Digital mammography: an update Hailey D Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Hailey D. Digital mammography: an update. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Issues in Emerging Health Technologies Issue 91. 2006 Authors' objectives (...) This bulletin provides an update of the literature published since an assessment was done by the Canadian Coordinating Office for Health Technology Assessment (CCOHTA), in 2002 (Ho C, et al. Digital mammography versus filmscreen mammography: technical, clinical and economic assessments [Technology report no. 30]). Authors' conclusions Digital mammography can improve breast-image quality and storage through the digital capture of x-ray images. Large comparative studies indicate that the overall accuracy

2006 Health Technology Assessment (HTA) Database.

136. Diagnostic performance of digital versus film mammography for breast-cancer screening. (PubMed)

Diagnostic performance of digital versus film mammography for breast-cancer screening. Film mammography has limited sensitivity for the detection of breast cancer in women with radiographically dense breasts. We assessed whether the use of digital mammography would avoid some of these limitations.A total of 49,528 asymptomatic women presenting for screening mammography at 33 sites in the United States and Canada underwent both digital and film mammography. All relevant information was available (...) for 42,760 of these women (86.3 percent). Mammograms were interpreted independently by two radiologists. Breast-cancer status was ascertained on the basis of a breast biopsy done within 15 months after study entry or a follow-up mammogram obtained at least 10 months after study entry. Receiver-operating-characteristic (ROC) analysis was used to evaluate the results.In the entire population, the diagnostic accuracy of digital and film mammography was similar (difference between methods in the area under

2005 NEJM

137. Impact of computer-aided detection prompts on the sensitivity and specificity of screening mammography

Impact of computer-aided detection prompts on the sensitivity and specificity of screening mammography Impact of computer-aided detection prompts on the sensitivity and specificity of screening mammography Journals Library An error has occurred in processing the XML document An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website

2005 NIHR HTA programme

138. Model of outcomes of screening mammography: information to support informed choices. (Full text)

Model of outcomes of screening mammography: information to support informed choices. To provide easy to use estimates of the benefits and harms of biennial screening mammography for women aged 40, 50, 60, and 70 years.Markov process model, with data from BreastScreen Australia, the Australian Institute of Health and Welfare, and the Australian Bureau of Statistics.Age specific outcomes expressed per 1000 women over 10 years.For every 1000 women screened over 10 years, 167-251 (depending on age (...) at screening). By comparison, among 1000 women aged 50 who decline screening, 20 cancers are diagnosed over 10 years. There are about 0.5, 2, 3, and 2 fewer deaths from breast cancer over 10 years per 1000 women aged 40, 50, 60, and 70, respectively, who choose to be screened compared with women who decline screening at times determined by relevant policy.Benefits and harms of screening mammography are relatively finely balanced. Quantitative estimates such as these can be used to support individual

2005 BMJ PubMed

139. Breast cancer mortality in Copenhagen after introduction of mammography screening: cohort study. (Full text)

Breast cancer mortality in Copenhagen after introduction of mammography screening: cohort study. To evaluate the effect on breast cancer mortality during the first 10 years of the mammography service screening programme that was introduced in Copenhagen in 1991.Cohort study.The mammography service screening programme in Copenhagen, Denmark.All women ever invited to mammography screening in the first 10 years of the programme. Historical, national, and historical national control groups were

2005 BMJ PubMed

140. Screening mammography: a reassessment

Screening mammography: a reassessment Screening mammography: a reassessment Screening mammography: a reassessment Deck W, Kakuma R Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Deck W, Kakuma R. Screening mammography: a reassessment. Montreal: Agence d'evaluation des technologies et des modes d'intervention en sante (AETMIS). AETMIS 05 (...) -03 RE. 2005 Authors' objectives This update of two reports by the Conseil d'Evaluation des technologies de la sante (CETS) published in 1990 and 1993 addresses three questions: (1) What is the strength of the scientific evidence on which screening mammography programs are based? (2) What evidence is there in support of screening for women aged 40 to 49 years? (3) What are the implications of research studies for maximizing the effectiveness of modern programs such as the Programme quebecois de

2005 Health Technology Assessment (HTA) Database.